Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Squamous Cell Carcinoma of Head and Neck 8Oropharyngeal Neoplasms 7Cholangiocarcinoma 7Pancreatic Neoplasms 6Lung Neoplasms 6Urinary Bladder Neoplasms 5Ovarian Neoplasms 4Mouth Neoplasms 4Laryngeal Neoplasms 4Gallbladder Neoplasms 4Carcinoma 4Sarcoma 3Hypopharyngeal Neoplasms 3Fallopian Tube Neoplasms 3Urethral Neoplasms 2Stomach Neoplasms 2Peritoneal Neoplasms 2Paranasal Sinus Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Mesothelioma, Malignant 2Klatskin Tumor 2Colorectal Neoplasms 2Vulvar Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Stomatitis 1

Interventions

Gemcitabine 2Cystectomy 2Cisplatin 2transplatin 1pembrolizumab 1pegfilgrastim 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Platinum 1Chemoradiotherapy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Infiltrating Bladder Urothelial Carcinoma × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT02944357 2017-11-17

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

Mayo Clinic

Phase NA Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡